Cellis AG

Cellis AG is a European biotechnology company focused on cell-based oncology therapy, with operations in Zug, Switzerland and Warsaw, Poland. The company describes itself as a biotech developing a new generation of cell-based therapies for solid tumors, built around a proprietary platform it calls the Macrophage Drug Conjugate (MDC) platform. Cellis positions its science as exploiting the biology of the tumor microenvironment: rather than only delivering a drug to a tumor, its approach is designed to use macrophages to deliver therapeutic payloads directly into the cytoplasm of cancer cells and, in doing so, to activate anti-tumor immunity from within the tumor. The central scientific claim behind the platform is a mechanism Cellis calls TRAIN, through which macrophages efficiently deliver a wide range of therapeutic payloads into cancer cells. This intracellular delivery is intended to induce tumor cell death and to generate damage-associated molecular patterns (DAMPs) — danger signals released by stressed and dying cells. Those DAMPs are then recognized by macrophages already present in the tumor microenvironment, providing a biological signal that can reprogram local macrophages and shift the microenvironment from one that supports tumor growth toward one more permissive to anti-tumor immunity. Cellis describes this as a self-amplifying mechanism of tumor attack and summarizes its vision as "turning the tumor against itself." Cellis operates as a multi-product pipeline company, using its technology platform to generate a portfolio of therapies intended to move toward the clinic. Its public materials reference research projects and named programs including MACOV and MISAME, and the company states that preparation is underway to progress its technology to first-in-human clinical trials in Q4 2026. The company emphasizes that it has received both private and public European financing, and that its projects are co-financed by the European Union. Organizationally, Cellis is a corporate group with a Swiss entity, Cellis AG, headquartered at Gubelstrasse 15, 6300 Zug, and a Polish entity, Cellis Sp. z o.o., at Gen. Zajaczka 26, 01-510 Warsaw. The company presents itself as founded on the broad and deep experience of an international team with expertise in scientific research and clinical development. It maintains a presence on LinkedIn and a public contact address at office@cellis.eu. As a privately held biotech, it is not known to be listed on a public stock exchange.

Cellis AG is a European biotechnology company focused on cell-based oncology therapy. It operates through a Swiss entity, Cellis AG, based in Zug, Switzerland, and a Polish entity, Cellis Sp. z o.o., based in Warsaw, Poland. The company presents itself as founded on the broad and deep experience of an international team with strong expertise in scientific research and clinical development. Cellis has developed a platform technology it calls the Macrophage Drug Conjugate (MDC) platform. According to the company, MDC is enabled by its discovery of a biologic mechanism named TRAIN, through which macrophages efficiently deliver a wide range of therapeutic payloads directly into the cytoplasm of cancer cells. This targeted intracellular delivery is designed to induce tumor cell death and to generate damage-associated molecular patterns (DAMPs), which are danger signals released by stressed and dying cells. These DAMPs are recognized by macrophages already present within the tumor microenvironment, providing a biological signal that can activate and reprogram local macrophages and shift the tumor microenvironment from one that supports tumor growth toward one more permissive to anti-tumor immunity. Cellis describes this as a self-amplifying mechanism of tumor attack and frames its vision as turning the tumor against itself. The company uses its technology platform to generate a multi-product portfolio intended to drive the development of therapies toward the clinic. Its public materials reference research projects and named programs including MACOV and MISAME. Cellis states that preparation is underway to progress its technology to first-in-human clinical trials in Q4 2026. Cellis reports that it has received private and public European financing, and that its projects are co-financed by the European Union. It maintains a corporate presence on LinkedIn and a public contact address at office@cellis.eu. The company is headquartered at Gubelstrasse 15, 6300 Zug, Switzerland, with its Polish operations at Gen. Zajaczka 26, 01-510 Warsaw. As a privately held biotech, it is not known to be publicly listed.

• Cellis states that preparation is underway to progress its technology to first-in-human clinical trials in Q4 2026.

A European biotech developing next-generation cell-based therapies for solid tumors, positioning its MDC platform as a way to turn the tumor against itself by activating anti-tumor immunity from within.

• Macrophage Drug Conjugate (MDC) platform

  A proprietary platform designed to exploit the biology of the tumor microenvironment to attack cancer and activate anti-tumor immunity from within.

• TRAIN mechanism

  A biologic mechanism discovered by Cellis through which macrophages efficiently deliver a wide range of therapeutic payloads directly into the cytoplasm of cancer cells.

• MACOV

  A research project referenced in Cellis public materials.

• MISAME

  A research project referenced in Cellis public materials.

1. 1Home - cellis.eucellis.eu
2. 2About us - cellis.eucellis.eu
3. 3Cellis AG - Wikidatawikidata.org